(Reuters) – Capricor Therapeutics Inc said on Wednesday it had put on hold a clinical trial of its drug to treat Duchenne muscular dystrophy (DMD), a muscle-wasting disorder, citing a safety review. The review follows a severe allergic reaction during infusion of the drug, the company said in a filing here. The patient responded well… Read More: U.S. drug developer Capricor places Duchenne drug trial on hold »
Benjamin Crump (Scott Olson/Getty Images) A new federal lawsuit has been filed against Gilead Sciences alleging that the pharmaceutical giant of putting profits over people. According to the Jacksonville Free Press, civil rights attorney Benjamin Crump believes the company is intentionally withholding a safer HIV drug from hundreds of thousands of patients — particularly those in… Read More: Civil rights attorney launches suit charging company with withholding new… »
By DAVID SHAYWITZ MD At long last, we seem to be on the threshold of departing the earliest phases of AI, defined by the always tedious “will AI replace doctors/drug developers/occupation X?” discussion, and are poised to enter the more considered conversation of “Where will AI be useful?” and “What are the key barriers to… Read More: AI Doesn’t Ask Why — But Physicians And Drug Developers… »
Anti-obesity drug Saxenda has been one of Novo Nordisk’s key growth drivers lately—and apparently, a Korean wholesaler noticed. The pharmaceutical middleman allegedly smuggled the popular drug into China, where it’s not yet approved. Korean regulators are investigating the wholesaler for allegedly hawking Saxenda in China, Korea Biomedical Review reported, citing multiple sources. A Novo spokeswoman confirmed to FiercePharma… Read More: Lured by high demand, Korean wholesaler smuggled Novo’s obesity drug… »